生化/生理作用
Tarenflurbil (or R-flurbiprofen) is an R enantiomer of racemic NSAID flurbiprofen that does not inhibit either cyclooxygenase 1 (COX-1) or cyclooxygenase 2 (COX-2). Tarenflurbil potently reduces levels of beta amyloid in human cells through direct inhibition of γ-secretase.
警示用语:
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Oral - Repr. 2 - Skin Sens. 1B
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Journal of neurochemistry, 83(4), 1009-1012 (2002-11-08)
Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced risk for Alzheimer's disease (AD) and selected NSAIDs racemates suppress beta-amyloid (Abeta) accumulation in vivo and Abeta42 production in vitro. Clinical use of NSAIDs for preventing or treating AD has been
The Journal of clinical investigation, 112(3), 440-449 (2003-08-05)
Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower
The Journal of pharmacy and pharmacology, 70(1), 59-69 (2017-10-17)
R-flurbiprofen (R-FP) was found to offer neuroprotective effects by inhibiting mitochondrial calcium overload induced by β-amyloid peptide toxicity in Alzheimer's disease (AD). However, poor brain penetration after oral administration posed a challenge to its further development for AD treatment. In
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门